30 January 2026 - Samsung Bioepis said Friday it has reached an agreement with US based firm Regeneron and Germany’s Bayer to commercialise Opuviz, an ophthalmic biosimilar to Eylea (aflibercept), in multiple markets outside the United States and Canada.

The agreement covers the low-concentration formulation of Samsung’s Opuviz (40 mg/mL). Under the deal, the Korean biosimilar firm plans to launch the drug in the United Kingdom from January 2026, across other European countries from April 2026, and in global markets from May 2026.

Read Korea Herald article